“…Curettage alone or systemic methotrexate administration, as well as expectant management, are strongly considered unsuitable because of the high morbidity and mortality maternal risks (hemorrhage, perforation, development of uterine arteriovenous malformation, etc. [ 7 , 8 , 9 , 10 , 11 ]). However, there is no consensus for the optimal treatment regime, and different situations require different approaches [ 12 , 13 ].…”